Literature DB >> 14710358

The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review.

A Denley1, J C Wallace, L J Cosgrove, B E Forbes.   

Abstract

The insulin receptor plays a vital role in mediating the actions of insulin. These include metabolic and mitogenic effects. This review will focus on the role of the insulin receptor isoforms in normal development and the pathogenesis of certain cancers and type 2 diabetes. There are two insulin receptor isoforms arising from the alternative splicing of exon 11 resulting in either the exon 11+ (IR-B) isoform (including 12 amino acids encoded by exon 11) or the exon 11- (IR-A) isoform. The isoforms have different affinities for insulin, IGF-II and IGF-I with the exon 11- isoform binding both insulin and IGF-II with high affinities. Interestingly, differential expression of the insulin receptor isoforms has been demonstrated in disease. Several cancer cell types that also overexpress IGF-II preferentially express the exon 11- isoform. Activation of the exon 11- insulin receptor by IGF-II and insulin results in mitogenic effects and a potentiation of the cancer phenotype. Also hyperinsulinemia has been associated with increased risk of cancer. Differential expression of the insulin receptor isoforms has also been demonstrated in type 2 diabetes although there is some discrepancy in the literature as to which isoform is expressed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14710358     DOI: 10.1055/s-2004-814157

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  36 in total

1.  Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer.

Authors:  Jin-Soo Kim; Edward S Kim; Diane Liu; J Jack Lee; Luisa Solis; Carmen Behrens; Scott M Lippman; Waun Ki Hong; Ignacio I Wistuba; Ho-Young Lee
Journal:  Cancer       Date:  2011-09-22       Impact factor: 6.860

2.  Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors.

Authors:  A M Hennige; V Strack; E Metzinger; G Seipke; H-U Häring; M Kellerer
Journal:  Diabetologia       Date:  2005-07-29       Impact factor: 10.122

3.  Sex-Specific Associations of Maternal Gestational Glycemia with Hormones in Umbilical Cord Blood at Delivery.

Authors:  Emily Oken; Emma Morton-Eggleston; Sheryl L Rifas-Shiman; Karen M Switkowski; Marie-France Hivert; Abby F Fleisch; Christos Mantzoros; Matthew W Gillman
Journal:  Am J Perinatol       Date:  2016-08-04       Impact factor: 1.862

Review 4.  Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

Authors:  Mónica Enguita-Germán; Puri Fortes
Journal:  World J Hepatol       Date:  2014-10-27

Review 5.  Insulin-like growth factor: current concepts and new developments in cancer therapy.

Authors:  Erin R King; Kwong-Kwok Wong
Journal:  Recent Pat Anticancer Drug Discov       Date:  2012-01       Impact factor: 4.169

6.  Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation.

Authors:  A C Sprynski; D Hose; A Kassambara; L Vincent; M Jourdan; J F Rossi; H Goldschmidt; B Klein
Journal:  Leukemia       Date:  2010-09-16       Impact factor: 11.528

7.  Role of insulin receptor and balance in insulin receptor isoforms A and B in regulation of apoptosis in simian virus 40-immortalized neonatal hepatocytes.

Authors:  Carmen Nevado; Manuel Benito; Angela M Valverde
Journal:  Mol Biol Cell       Date:  2008-01-02       Impact factor: 4.138

8.  A novel approach to identify two distinct receptor binding surfaces of insulin-like growth factor II.

Authors:  Clair L Alvino; Kerrie A McNeil; Shee Chee Ong; Carlie Delaine; Grant W Booker; John C Wallace; Jonathan Whittaker; Briony E Forbes
Journal:  J Biol Chem       Date:  2009-01-12       Impact factor: 5.157

9.  Reduced insulin-like growth factor I receptor and altered insulin receptor isoform mRNAs in normal mucosa predict colorectal adenoma risk.

Authors:  M Agostina Santoro; Sarah F Andres; Joseph A Galanko; Robert S Sandler; Temitope O Keku; P Kay Lund
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-13       Impact factor: 4.254

10.  New target genes for the peroxisome proliferator-activated receptor-γ (PPARγ) antitumour activity: Perspectives from the insulin receptor.

Authors:  Daniela P Foti; Francesco Paonessa; Eusebio Chiefari; Antonio Brunetti
Journal:  PPAR Res       Date:  2009-06-29       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.